Sarepta’s Gene Therapy Impresses In Limb-Girdle Muscular Dystrophy
Pivotal Study Planned For 2021
Positive functional results from Sarepta’s SRP-9003 gene therapy in limb-girdle muscular dystrophy type 2E bodes well for a pivotal study, and for the company’s studies of other potential gene therapies in Duchenne muscular dystrophy.
